Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, was approved as a conventional insulin sensitizer in the treatment of type 2 diabetes mellitus [26]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.